Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating the safety and tolerability of XmAb13676 (plamotamab) in CD20-expressing hematologic malignancies has co…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL [Phase 1]
Phase 1 trial evaluating haploidentical stem cell transplantation with prophylactic natural killer donor lymphocyte infusion in lymphoma, mu…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: MargheRITA (Remote Intelligence for Therapeutic Adherence) [NA]
A completed clinical trial named MargheRITA (Remote Intelligence for Therapeutic Adherence) sponsored by Advice Pharma Group srl studied tre…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating zanubrutinib in combination with obinutuzumab in untreated chronic lymphocytic leukemia or small lymphoc…
-
EMA approval · 2024-10-21EMA Authorised: Zydelig (Idelalisib) — Gilead Sciences Ireland UC
EMA authorised Zydelig (idelalisib) for certain non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL [Phase 2]
Phase 2 study evaluating idelalisib plus ofatumumab in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma; the…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study of the intravenous agent S65487 in relapsed or refractory hematologic cancers (acute myeloid leukemia, non-Hodgkin lymphoma, m…
-
CLINICAL_TRIALS withdrawal · 2024-10-15Clinical Trial Update: Cardiotoxicities in Patients Receiving BTKi
A clinical trial evaluating cardiotoxicities in patients receiving Bruton's tyrosine kinase inhibitors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-03Clinical Trial Update: B-Cell Hematologic Malignancy Vaccination Registry
A clinical trial update indicates that the B-cell hematologic malignancy vaccination registry (NCT02298816) sponsored by Wake Forest Univers…
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating KLS-1 as a monotherapy for malignant neoplasms, including chronic lymphocytic leukemia and solid tumors; …
-
CLINICAL_TRIALS trial_result · 2024-09-26Clinical Trial Update: Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with high-frequency, low-dose subcutaneous rituximab in previously untreated chronic l…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 2]
Phase 2 trial update showing results for ofatumumab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma, with trial res…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
Open-label extension Phase 3 study in patients aged 65 and older with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma; results po…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]
Phase I study of CYC140, a PLK-1 inhibitor, in advanced leukemias and myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies [Phase 1]
Phase 1 study of CAR20.19.22 T-cells in relapsed/refractory B-cell malignancies has been terminated.
-
FDA approval · 2024-09-11FDA Approved: LENALIDOMIDE — Original Application (Novugen Pharma (USA) LLC)
FDA approved the original application for lenalidomide from Novugen Pharma (USA) LLC, enabling a generic version of the cancer drug lenalido…
-
CLINICAL_TRIALS trial_result · 2024-08-22Clinical Trial Update: A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma [Phase 1]
Phase I dose-escalation study evaluating the safety and pharmacokinetics of LAM-002A in patients with Non-Hodgkin lymphoma and chronic lymph…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
A real-world study evaluating a BTK inhibitor for chronic lymphocytic leukemia in China; the trial status is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies [Phase 1]
Phase 1 trial update for CLBR001 and SWI019 in relapsed/refractory B-cell malignancies has completed enrollment in a study targeting multipl…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
First-in-human study of GEN3009 in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated, with results posted thereafter.
-
CLINICAL_TRIALS research · 2024-08-13Clinical Trial Update: A Study of FCN-338 in Patients With Chronic CLL/SLL [Phase 1]
FCN-338 is being evaluated in a Phase 1 trial for chronic lymphocytic leukemia and small lymphocytic lymphoma, with the study currently acti…
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 1]
Phase 1 trial evaluating a triple combination of zanubrutinib, obinutuzumab, and lenalidomide in newly diagnosed chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating intermittent dosing of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic…